Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) has been featured in a NetworkNewsAudio editorial highlighting its novel approach to treating multiple sclerosis (MS), a chronic neurodegenerative disease affecting millions worldwide. The audio press release, titled "Novel Patented Myelin Drug-Discovery Strategy Targets Massive Unmet Need in Multiple Sclerosis", accompanies a previously published editorial discussing the urgent need for therapies that go beyond symptom management. The global MS therapeutics market is projected to reach $38.62 billion by 2030, underscoring the significant commercial opportunity for disease-modifying treatments.
Quantum BioPharma's lead candidate, Lucid-MS, is a patented, first-in-class drug candidate designed to target the myelin sheath directly, with the goal of preventing, stopping, and potentially reversing its degradation. This approach is intended to address the substantial unmet need for treatments that can alter the course of MS, rather than merely alleviating symptoms. The company's focus on myelin repair represents a paradigm shift in MS therapy, as current disease-modifying therapies primarily target the immune system to reduce inflammation but do not directly address myelin damage.
According to the National Multiple Sclerosis Society, approximately 2.8 million people worldwide live with MS, and the majority eventually transition to a progressive form of the disease for which few treatments exist. The potential for a therapy that could repair myelin would be transformative for patients, as it could restore nerve function and slow or halt disability progression. Quantum BioPharma's preclinical data have shown that Lucid-MS can prevent and reverse myelin degradation, providing a strong scientific rationale for advancing into clinical trials.
The company is also pursuing other therapeutic areas, including neurodegenerative and metabolic disorders, as well as alcohol misuse disorders. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc., Quantum is dedicated to building a portfolio of innovative biotech solutions. Additionally, Quantum invented UNBUZZD(TM), an over-the-counter product for alcohol metabolism, and retains a 19.84% ownership stake in Unbuzzd Wellness Inc., along with royalty payments on sales.
Given the high unmet need and the projected market growth, Quantum BioPharma's Lucid-MS could capture significant market share if clinical trials confirm its efficacy and safety. Investors and stakeholders can find the latest news and updates about QNTM in the company's newsroom at https://nnw.fm/QNTM. The full press release and audio feature are available at https://nnw.fm/eI6Gv.
